Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure

Huaqian XU; Xue LI; Shanhong TANG

doi:10.3969/j.issn.1001-5256.2022.08.041

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1927-1930

PDF( 1872 KB)

Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.08.041

Huaqian XU^{1, 2},
Xue LI^{1, 2},
Shanhong TANG^{1, 2
,
,
,}

1.
School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
2.
Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China

Research funding:

Scientific Research Project of Sichuan Provincial Health Commission (20PJ180)

More Information

Corresponding author: TANG Shanhong, 15928956390@163.com(ORCID: 0000-0001-6652-2942)
Received Date: 2021-12-29
Accepted Date: 2022-02-17
Published Date: 2022-08-20

Abstract

Abstract

Acute-on-chronic liver failure (ACLF) is a clinical syndrome with rapid deterioration of liver function caused by a series of predisposing factors on the basis of chronic liver diseases, and it is characterized by multiple organ failure and high short-term mortality. The onset of systemic inflammation is one of the important influencing factors for the progression of ACLF and is the body's natural defense against infection; however, the excessive release of inflammatory mediators breaks the original dynamic balance between "pro-inflammation" and "anti-inflammation", which may aggravate liver function impairment and even lead to decompensation. Therefore, the intensity of inflammatory response is closely associated with the prognosis of patients with ACLF, while at present, not enough attention has been paid to the impact of inflammatory response on patients with ACLF and the measures to deal with cytokine storm. Therefore, this article summarizes the impact of inflammatory response on ACLF and related advances in treatment, so as to provide ideas for the diagnosis and treatment of ACLF in clinical practice.
- Acute-On-Chronic Liver Failure,
- Inflammation,
- Therapeutics,
- Prognosis

FullText(HTML)

References(36)

References

[1]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(6): 826-828. DOI: 10.1007/s12072-019-09980-1.
[2]	BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(10): 1113-1125. DOI: 10.1111/apt.12695.
[3]	ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
[4]	TANG SH, ZENG WZ, JIANG MD, et al. Research progress in prediction of clinical outcome in patients with liver failure[J]. J Clin Hepatol, 2015, 31(1): 135-138. DOI: 10.3969/j.issn.1001-5256.2015.01.031. 汤善宏, 曾维政, 蒋明德, 等. 肝衰竭患者临床预后判断研究进展[J]. 临床肝胆病杂志, 2015, 31(1): 135-138. DOI: 10.3969/j.issn.1001-5256.2015.01.031.
[5]	ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[6]	MICHELENA J, ALTAMIRANO J, ABRALDES JG, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis[J]. Hepatology, 2015, 62(3): 762-772. DOI: 10.1002/hep.27779.
[7]	CULLARO G, SHARMA R, TREBICKA J, et al. Precipitants of acute-on-chronic liver failure: an opportunity for preventative measures to improve outcomes[J]. Liver Transpl, 2020, 26(2): 283-293. DOI: 10.1002/lt.25678.
[8]	ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2021, 3(1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
[9]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
[10]	van WYNGENE L, VANDEWALLE J, LIBERT C. Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?[J]. EMBO Mol Med, 2018, 10(8): e8712. DOI: 10.15252/emmm.201708712.
[11]	BAJAJ JS, VARGAS HE, REDDY KR, et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 756-765. e3. DOI: 10.1016/j.cgh.2018.07.022.
[12]	VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis[J]. J Hepatol, 2021, 75(3): 589-599. DOI: 10.1016/j.jhep.2021.04.022.
[13]	PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380. e10. DOI: 10.1053/j.gastro.2018.12.005.
[14]	FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
[15]	FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18(4): 963-973. e14. DOI: 10.1016/j.cgh.2019.07.055.
[16]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391(10138): 2417-2429. DOI: 10.1016/S0140-6736(18)30840-7.
[17]	FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157(1): 149-162. DOI: 10.1053/j.gastro.2019.03.021.
[18]	GUSTOT T, JALAN R. Acute-on-chronic liver failure in patients with alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 319-327. DOI: 10.1016/j.jhep.2018.12.008.
[19]	ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
[20]	ZHANG YC, BI YZ, FANG X, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35(7): 1570-1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029. 张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志, 2019, 35(7): 1570-1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029.
[21]	PHILIPS CA, PHADKE N, GANESAN K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis[J]. Indian J Gastroenterol, 2018, 37(3): 215-225. DOI: 10.1007/s12664-018-0859-4.
[22]	MULLISH BH, MCDONALD J, THURSZ MR, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66(4): 1354-1355. DOI: 10.1002/hep.29369.
[23]	HARTMANN P, HOCHRATH K, HORVATH A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice[J]. Hepatology, 2018, 67(6): 2150-2166. DOI: 10.1002/hep.29676.
[24]	GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46(11-12): 1029-1036. DOI: 10.1111/apt.14361.
[25]	ACHARYA C, SAHINGUR SE, BAJAJ JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis[J]. JCI Insight, 2017, 2(19): e94416. DOI: 10.1172/jci.insight.94416.
[26]	FISCHER P, STEFANESCU H, HATEGAN R, et al. Bacterial infection-related acute-on-chronic liver failure: The standpoint matters![J]. J Hepatol, 2021, 75(4): 1009-1010. DOI: 10.1016/j.jhep.2021.04.046.
[27]	WU B, DU LY, MA YJ, et al. Effects of different combinations of artificial liver support system on efficacy and inflammatory indexes of patients with hepatitis B virus-related acute-on-chronic liver failure in early and middle stages[J/CD]. Chin J Liver Dis(Electr Version), 2021, 13(1): 32-38. DOI: 10.3969/j.issn.1674-7380.2021.01.006. 吴蓓, 杜凌遥, 马元吉, 等. 不同组合人工肝支持系统治疗乙型肝炎病毒相关早、中期慢加急性肝衰竭患者的疗效及对炎症指标的影响[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 32-38. DOI: 10.3969/j.issn.1674-7380.2021.01.006.
[28]	GUO X, WU F, GUO W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure[J]. J Int Med Res, 2020, 48(6): 300060520932053. DOI: 10.1177/0300060520932053.
[29]	MAIWALL R, BAJPAI M, CHOUDHURY AK, et al. Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensity-score matched study from AARC[J]. Liver Int, 2021, 41(5): 1083-1096. DOI: 10.1111/liv.14806.
[30]	SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391. e3. DOI: 10.1053/j.gastro.2018.12.007.
[31]	KHANAM A, TREHANPATI N, RIESE P, et al. Blockade of neutrophil's chemokine receptors CXCR1/2 abrogate liver damage in acute-on-chronic liver failure[J]. Front Immunol, 2017, 8: 464. DOI: 10.3389/fimmu.2017.00464.
[32]	ANAND L, BIHARI C, KEDARISETTY CK, et al. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis[J]. Liver Int, 2019, 39(1): 115-126. DOI: 10.1111/liv.13923.
[33]	ENGELMANN C, MARTINO VD, KERBERT A, et al. The current status of granulocyte-colony stimulating factor to treatacute-on-chronic liver failure[J]. Semin Liver Dis, 2021, 41(3): 298-307. DOI: 10.1055/s-0041-1723034.
[34]	LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
[35]	AHMAD A, WALI AF, REHMAN MU, et al. Therapeutic potential of rhododendron arboreum polysaccharides in an animal model of lipopolysaccharide-inflicted oxidative stress and systemic inflammation[J]. Molecules, 2020, 25(24): 6045. DOI: 10.3390/molecules25246045.
[36]	WANG X, SUN M, YANG X, et al. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure[J]. Biomed Res Int, 2020, 2020(4): 1-7. DOI: 10.1155/2020/5062873.

Relative Articles

[1]	Wei JIANG, Xiujun CHANG, Fan ZENG, Yunping LAN. Current status of research on artificial intelligence in prognostic prediction models for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2024, 40(9): 1891-1896. doi: 10.12449/JCH240927
[2]	Yu WU, Jinling DONG, Manman XU, Huina CHEN, Huaibin ZOU, Li BAI, Yu CHEN. Acute－on－chronic liver failure： Features and prognosis of a new clinical classification system based on onset manifestations[J]. Journal of Clinical Hepatology, 2023, 39(10): 2375-2382. doi: 10.3969/j.issn.1001-5256.2023.10.015
[3]	Fuchun WANG, Wanjie ZHANG, Ziyi LI, Yongwu MAO, Aiping TIAN, Xiaorong MAO, Junfeng LI. Value of Charlson comorbidity index in predicting the prognosis of patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(5): 1098-1104. doi: 10.3969/j.issn.1001-5256.2023.05.015
[4]	Honglian DU, Ye LI, Bo WANG, Linkun MA, Tiantian HU, Yunjian SHENG, Wen CHEN, Gang WU, Cunliang DENG. Value of indocyanine green clearance test combined with total bilirubin actual resident rate in evaluating the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure after artificial liver support system therapy[J]. Journal of Clinical Hepatology, 2023, 39(2): 307-315. doi: 10.3969/j.issn.1001-5256.2023.02.009
[5]	Qian ZHANG, Tao HAN. Prognostic evaluation of acute－on－chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2301-2306. doi: 10.3969/j.issn.1001-5256.2023.10.006
[6]	Yuhang CHEN, Zimeng JIANG, Zhijiao ZHANG, Mengyao ZHENG, Meilian WANG, Hua HUANG, Gongfang ZHAO. The influence of diagnostic criteria of different guidelines on short-term prognosis of artificial liver therapy for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(11): 2629-2634. doi: 10.3969/j.issn.1001-5256.2023.11.017
[7]	Tingting DENG, Li LI, Ying GUAN, Xueyan LUO, Kun QIN, Min LIU. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(10): 2346-2351. doi: 10.3969/j.issn.1001-5256.2022.10.028
[8]	Wanshu LIU, Lijun SHEN, Qinghui ZHAI, Shaojie XIN, Shaoli YOU. Risk factors for acute variceal bleeding in acute-on-chronic liver failure and its influence on prognosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2532-2536. doi: 10.3969/j.issn.1001-5256.2022.11.018
[9]	Nuo SI, Fang LIU, Lei LIU, Hua LIU, Yingying CAO, Juan LI, Jing LIANG. Effect of platelet level and platelet parameters on the prognosis of patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 381-386. doi: 10.3969/j.issn.1001-5256.2022.02.023
[10]	Yuyu ZENG, Dakai GAN, Nengwen XIE, Jiao WAN, Molong XIONG. Prognosis and adverse reactions of patients with acute-on-chronic liver failure receiving artificial liver support therapy stratified by international normalized ratio[J]. Journal of Clinical Hepatology, 2022, 38(10): 2308-2312. doi: 10.3969/j.issn.1001-5256.2022.10.020
[11]	Chenrui LIU, Yaping LI, Sen LUO, Dandan FENG, Fengping WU, Song ZHAI, Shuangsuo DANG. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 56-62. doi: 10.3969/j.issn.1001-5256.2021.01.012
[12]	Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
[13]	Jian LI, Yaqiu DU, Dezhao LI, Huifan JI, Chenggang ZHANG, Qingxia LIU, Xiaolin GUO. Current status of research on the prognostic markers for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(11): 2701-2705. doi: 10.3969/j.issn.1001-5256.2021.11.047
[14]	Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
[15]	Wang XianBo, Zhang Qun, Gao FangYuan. Prediction of acute-on-chronic liver failure and integrated traditional Chinese and Western medicine therapy[J]. Journal of Clinical Hepatology, 2020, 36(1): 19-25. doi: 10.3969/j.issn.1001-5256.2020.01.003
[16]	Yang ShuJuan, Tian Zhen, He YingLi, Zhao YingRen, Zhang Jing, Lu: HengYi, Song HongBo. Predisposing factors for acute-on-chronic liver failure and their influence on prognosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 128-131. doi: 10.3969/j.issn.1001-5256.2020.01.028
[17]	Dou HongLian, He HongYan, Xiao CiJun, Wang Bo, Li Ye, Sheng YunJian, Deng CunLiang. Value of indocyanine green clearance test in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(12): 2759-2764. doi: 10.3969/j.issn.1001-5256.2019.12.024
[18]	Tong JingJing, Mu XiuYing, Xu Xiang, Chen Jing, Zhai XingRan, Wang Yu, Su HaiBin, Liu XiaoYan, Hu JinHua. Association between blood ammonia and 90-day prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2019.06.024
[19]	Liu Juan, Bai FeiYun, Zhang Jing. Research advances in diagnostic criteria for acute-on-chronic liver failure and models for prognostic evaluation[J]. Journal of Clinical Hepatology, 2019, 35(6): 1384-1387. doi: 10.3969/j.issn.1001-5256.2019.06.046
[20]	Wang JiaXin, Cheng Na, Xiang TianXin, Li ShuYue, Xiao JinPing, Wu XiaoPing. Establishment and evaluation of short-term prognostic model for hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2019.06.023

Supplements(0)

Cited By

Cited by

Periodical cited type(25)

1.	陈炜. 终末期肝病模型联合血清钠评分对肝衰竭患者短期预后的预测价值. 川北医学院学报. 2024(02): 247-251 .
2.	王学英. MELD-Na评分联合NLR预测肝硬化食管胃静脉曲张破裂出血后再出血的临床价值. 罕少疾病杂志. 2024(05): 70-72 .
3.	林小洪，吴文楠，荀振. 血小板-白蛋白-胆红素评分与肝硬化患者肝功能Child-Turcotte-Pugh分级的相关性分析. 福建医科大学学报. 2024(01): 37-43 .
4.	孙玉，秦维，王丹，郑艳丽，霍玉玲. 前白蛋白及纤维蛋白原水平与代偿期肝硬化食管静脉曲张发生的关系. 中国肝脏病杂志(电子版). 2024(02): 7-12 .
5.	石红. 延续性护理服务方案对肝硬化食管胃静脉曲张内镜下精准断流术后的临床影响研究. 基层医学论坛. 2024(20): 114-116+142 .
6.	李欣忆，李娇娇，孙蔚. 肝硬化食管胃底静脉曲张破裂出血患者经颈静脉肝内门体分流术后发生显性肝性脑病的列线图预测模型建立及评价. 临床肝胆病杂志. 2024(08): 1605-1611 . 本站查看
7.	杨丹，周健. 多种无创预测模型在肝硬化门静脉高压中的研究进展. 中国临床研究. 2024(11): 1778-1783 .
8.	陈刚，谷光丽，何映雪，唐尧. 血清表皮生长因子对肝硬化食管胃静脉曲张患者再出血的诊断价值分析. 转化医学杂志. 2024(10): 1698-1702 .
9.	喻雪珂，黎孟玲，彭思远，申月明，梁纶熙，曾亚. 食管胃底静脉曲张破裂出血对肝硬化患者1年死亡结局的影响及相关因素研究. 中国全科医学. 2023(14): 1745-1752 .
10.	郝艳萍，韩靓，仇晶辉，滕圣智，王建华. 乙肝肝硬化食管胃静脉曲张急性出血患者内镜下治疗后发生菌血症的危险因素分析. 中国消毒学杂志. 2023(03): 182-184 .
11.	顾达，童聪，赵祥安，向晓星. PC/SD、FIB-4指数、CTP评分、MELD评分、MELD-Na评分在预测肝硬化食管静脉曲张出血套扎术后1年内再出血的价值评估. 胃肠病学和肝病学杂志. 2023(03): 289-294 .
12.	朱会明，张华，张金荣，吴雪华，吴柳，刘义安. 肝硬化血瘀证患者食管胃底静脉曲张相关性研究. 中国中医急症. 2023(04): 665-668 .
13.	周苏云，周影，程新月. 肝硬化患者发生肝性脑病的影响因素分析及对预检分诊意义的探讨. 中西医结合护理(中英文). 2023(03): 130-132 .
14.	葛琴. 血府逐瘀汤联合双歧杆菌三联活菌治疗酒精性肝硬化的疗效研究. 中医临床研究. 2023(20): 142-145 .
15.	邱荣金，卢劲瑜，苏雪梅，郑凤祥，廖丽芳. 预防使用抗生素对食管胃静脉曲张内镜下治疗的影响评估. 中国现代药物应用. 2023(19): 99-101 .
16.	邢恩涛，赵孟杰，金鹏飞，武振东，刘志春. 肝硬化门静脉高压TIPS术后HVPG下降相关因素. 青岛大学学报(医学版). 2023(05): 759-762 .
17.	刘媛，徐建光，何雪云，万秀萍，林小花，王莉娟，郑临海. 血钙浓度联合MELD评分对肝硬化严重程度的预测价值. 浙江中西医结合杂志. 2022(02): 129-130+149 .
18.	张春燕，田正方，朱经科，晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析及干预对策. 黑龙江医药科学. 2022(02): 96-99 .
19.	俞斌，屠军，沈玉玲. AIMS65评分预测肝硬化食管胃底静脉曲张破裂出血患者死亡的价值. 胃肠病学和肝病学杂志. 2022(07): 737-742 .
20.	刘益，周自忠，刘刚，徐海荣. 食管胃底静脉曲张破裂出血患者急诊TIPS术后肝性脑病发生特征及危险因素分析. 肝脏. 2022(06): 658-661 .
21.	廖翔. 肝硬化患者SAAG与食管胃底静脉曲张破裂出血的关系研究. 现代诊断与治疗. 2022(11): 1646-1648+1692 .
22.	张春燕，田正方，朱经科，晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析. 黑龙江医药科学. 2022(05): 171-173 .
23.	曾伍姣，张知洪，陈令民，李亦明. 血管紧张素Ⅱ水平在肝硬化患者诊断中的应用及与MELD评分关系研究. 肝胆外科杂志. 2021(01): 60-63 .
24.	祝强，杨继敏，刘中亮. 八种评分系统对肝硬化失代偿期患者短期预后的预测价值. 中国医药科学. 2021(19): 18-22 .
25.	赵媛，赵明，范玉梅，邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 .

Other cited types(9)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (819) PDF downloads(90)

Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.08.041